Phase III trials with docetaxel-based combinations for metastatic castration-resistant prostate cancer: time to learn from past experiences.
作者信息
Antonarakis Emmanuel S, Eisenberger Mario A
出版信息
J Clin Oncol. 2013 May 10;31(14):1709-12. doi: 10.1200/JCO.2013.48.8825. Epub 2013 Apr 8.
Abstract
摘要
相似文献
1
Phase III trials with docetaxel-based combinations for metastatic castration-resistant prostate cancer: time to learn from past experiences.多西他赛联合用药治疗转移性去势抵抗性前列腺癌的Ⅲ期试验：是时候从过去的经验中吸取教训了。
J Clin Oncol. 2013 May 10;31(14):1709-12. doi: 10.1200/JCO.2013.48.8825. Epub 2013 Apr 8.
2
Chemotherapy for metastatic castration-sensitive prostate cancer.转移性去势敏感性前列腺癌的化疗
Int J Urol. 2016 Sep;23(9):726-33. doi: 10.1111/iju.13148. Epub 2016 Jun 26.
3
Docetaxel-based combination therapy for castration-resistant prostate cancer.多西他赛为基础的联合治疗用于去势抵抗性前列腺癌。
Ann Oncol. 2010 Nov;21(11):2135-2144. doi: 10.1093/annonc/mdq050. Epub 2010 Mar 29.
4
Taxane-based Combination Therapies for Metastatic Prostate Cancer.基于紫杉烷的联合治疗转移性前列腺癌。
Eur Urol Focus. 2019 May;5(3):369-380. doi: 10.1016/j.euf.2017.11.009. Epub 2017 Dec 21.
5
Abiraterone and its place in the treatment of metastatic CRPC.阿比特龙及其在转移性 CRPC 治疗中的地位。
Nat Rev Clin Oncol. 2013 Jan;10(1):6-8. doi: 10.1038/nrclinonc.2012.202. Epub 2012 Nov 13.
6
NICE guidance on abiraterone for castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen.英国国家卫生与临床优化研究所（NICE）关于阿比特龙用于先前接受含多西他赛方案治疗的去势抵抗性转移性前列腺癌的指南。
Lancet Oncol. 2012 Aug;13(8):762-3. doi: 10.1016/s1470-2045(12)70289-9.
7
[Prostate cancer: future strategies for chemotherapy management].
Ann Urol (Paris). 2007 Oct;41 Suppl 3:S77-9. doi: 10.1016/s0003-4401(07)80514-6.
8
Speeding dating for docetaxel and recent debutantes in castration-resistant prostate cancer: 'plus or minus' may be a minus.
Ann Oncol. 2013 Feb;24(2):270-272. doi: 10.1093/annonc/mds641.
9
Actual benefit of chemo-hormonal therapy in non-castrate metastatic prostate cancer.化疗联合激素治疗在非去势转移性前列腺癌中的实际获益
Future Oncol. 2015;11(8):1141-3. doi: 10.2217/fon.15.36.
10
引用本文的文献
1
Drug resistance in metastatic castration-resistant prostate cancer: an update on the status quo.转移性去势抵抗性前列腺癌中的耐药性：现状更新
Cancer Drug Resist. 2022 Jun 22;5(3):667-690. doi: 10.20517/cdr.2022.15. eCollection 2022.
2
Inhibition of Janus Kinase 1 synergizes docetaxel sensitivity in prostate cancer cells.抑制 Janus 激酶 1 可增强前列腺癌细胞对多西他赛的敏感性。
J Cell Mol Med. 2021 Sep;25(17):8187-8200. doi: 10.1111/jcmm.16684. Epub 2021 Jul 28.
3
Novel therapies are changing treatment paradigms in metastatic prostate cancer.新型疗法正在改变转移性前列腺癌的治疗模式。
J Hematol Oncol. 2020 Oct 28;13(1):144. doi: 10.1186/s13045-020-00978-z.
4
Cabozantinib plus docetaxel and prednisone in metastatic castration-resistant prostate cancer.卡博替尼联合多西他赛和泼尼松治疗转移性去势抵抗性前列腺癌。
BJU Int. 2021 Apr;127(4):435-444. doi: 10.1111/bju.15227. Epub 2020 Oct 23.
5
Radium-223 plus abiraterone in metastatic castration-resistant prostate cancer: a cautionary tale.镭-223联合阿比特龙治疗转移性去势抵抗性前列腺癌：一则警示故事。
Transl Androl Urol. 2019 Jul;8(Suppl 3):S341-S345. doi: 10.21037/tau.2019.05.02.
6
Phase II, Multicenter, Randomized Trial of Docetaxel plus Prednisone with or Without Cediranib in Men with Chemotherapy-Naive Metastatic Castrate-Resistant Prostate Cancer.多中心、随机 II 期临床试验：多西他赛联合泼尼松加或不加 Cediranib 治疗化疗初治转移性去势抵抗性前列腺癌男性患者。
Oncologist. 2019 Sep;24(9):1149-e807. doi: 10.1634/theoncologist.2019-0331. Epub 2019 May 31.
7
Immunotherapy for Prostate Cancer.前列腺癌的免疫治疗。
Cold Spring Harb Perspect Med. 2019 May 1;9(5):a030627. doi: 10.1101/cshperspect.a030627.
8
Treatment with docetaxel in combination with Aneustat leads to potent inhibition of metastasis in a patient-derived xenograft model of advanced prostate cancer.多西他赛联合安维汀治疗在晚期前列腺癌患者来源异种移植模型中可显著抑制转移。
Br J Cancer. 2018 Mar 20;118(6):802-812. doi: 10.1038/bjc.2017.474. Epub 2018 Jan 30.
9
A standardized herbal extract mitigates tumor inflammation and augments chemotherapy effect of docetaxel in prostate cancer.一种标准化的草药提取物可减轻肿瘤炎症，并增强多西他赛治疗前列腺癌的效果。
Sci Rep. 2017 Nov 15;7(1):15624. doi: 10.1038/s41598-017-15934-0.
10
The STAMPEDE trial: paradigm-changing data through innovative trial design.STAMPEDE试验：通过创新试验设计产生的改变范式的数据。
Transl Cancer Res. 2016 Sep;5(3 Suppl):S485-S490. doi: 10.21037/tcr.2016.09.08.
本文引用的文献
1
Aflibercept versus placebo in combination with docetaxel and prednisone for treatment of men with metastatic castration-resistant prostate cancer (VENICE): a phase 3, double-blind randomised trial.阿柏西普联合多西他赛和泼尼松治疗转移性去势抵抗性前列腺癌男性患者（VENICE）：一项 3 期、双盲、随机试验。
Lancet Oncol. 2013 Jul;14(8):760-8. doi: 10.1016/S1470-2045(13)70184-0. Epub 2013 Jun 4.
2
Phase III, randomized, placebo-controlled study of docetaxel in combination with zibotentan in patients with metastatic castration-resistant prostate cancer.多西他赛联合 Zibotentan 治疗转移性去势抵抗性前列腺癌的 III 期、随机、安慰剂对照研究。
J Clin Oncol. 2013 May 10;31(14):1740-7. doi: 10.1200/JCO.2012.46.4149. Epub 2013 Apr 8.
3
Randomized, double-blind, placebo-controlled phase III trial comparing docetaxel and prednisone with or without bevacizumab in men with metastatic castration-resistant prostate cancer: CALGB 90401.随机、双盲、安慰剂对照 III 期临床试验比较多西他赛和泼尼松与或不与贝伐珠单抗在转移性去势抵抗性前列腺癌男性患者中的疗效：CALGB 90401。
J Clin Oncol. 2012 May 1;30(13):1534-40. doi: 10.1200/JCO.2011.39.4767. Epub 2012 Mar 26.
4
Dasatinib combined with docetaxel for castration-resistant prostate cancer: results from a phase 1-2 study.达沙替尼联合多西他赛治疗去势抵抗性前列腺癌：来自 1-2 期研究的结果。
Cancer. 2012 Jan 1;118(1):63-71. doi: 10.1002/cncr.26204. Epub 2011 Jul 25.
5
End points and outcomes in castration-resistant prostate cancer: from clinical trials to clinical practice.去势抵抗性前列腺癌的终点和结局：从临床试验到临床实践。
J Clin Oncol. 2011 Sep 20;29(27):3695-704. doi: 10.1200/JCO.2011.35.8648. Epub 2011 Aug 22.
6
Expanding treatment options for metastatic prostate cancer.扩大转移性前列腺癌的治疗选择。
N Engl J Med. 2011 May 26;364(21):2055-8. doi: 10.1056/NEJMe1102758.
7
Randomized, open-label phase III trial of docetaxel plus high-dose calcitriol versus docetaxel plus prednisone for patients with castration-resistant prostate cancer.多西他赛联合高剂量骨化三醇与多西他赛联合泼尼松治疗去势抵抗性前列腺癌的随机、开放标签 III 期临床试验。
J Clin Oncol. 2011 Jun 1;29(16):2191-8. doi: 10.1200/JCO.2010.32.8815. Epub 2011 Apr 11.
8
Preliminary study of the specific endothelin a receptor antagonist zibotentan in combination with docetaxel in patients with metastatic castration-resistant prostate cancer.在转移性去势抵抗性前列腺癌患者中，内皮素 A 受体拮抗剂 zibotentan 联合多西他赛的初步研究。
Prostate. 2011 Sep;71(12):1264-75. doi: 10.1002/pros.21342. Epub 2011 Jan 26.
9
A phase 2 study of estramustine, docetaxel, and bevacizumab in men with castrate-resistant prostate cancer: results from Cancer and Leukemia Group B Study 90006.一项关于依托泊苷、多西他赛和贝伐珠单抗治疗去势抵抗性前列腺癌男性患者的 2 期研究：来自癌症和白血病组 B 研究 90006 的结果。
Cancer. 2011 Feb 1;117(3):526-33. doi: 10.1002/cncr.25421. Epub 2010 Sep 22.
10
Final safety and efficacy analysis of the specific endothelin A receptor antagonist zibotentan (ZD4054) in patients with metastatic castration-resistant prostate cancer and bone metastases who were pain-free or mildly symptomatic for pain: a double-blind, placebo-controlled, randomized Phase II trial.在无疼痛或仅有轻度疼痛症状的转移性去势抵抗性前列腺癌和骨转移患者中，特异性内皮素 A 受体拮抗剂 Zibotentan（ZD4054）的最终安全性和疗效分析：一项双盲、安慰剂对照、随机的 II 期试验。
BJU Int. 2010 Oct;106(7):966-73. doi: 10.1111/j.1464-410X.2010.09638.x.
Zotero 插件